NasdaqGM:TRHC

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Market Cap

US$1.0b

Last Updated

2021/07/28 02:52 UTC

Data Sources

Company Financials +

Executive Summary

Tabula Rasa HealthCare, Inc. operates as a healthcare technology company in the United States. More Details


Snowflake Analysis

Slightly overvalued with imperfect balance sheet.

Share Price & News

How has Tabula Rasa HealthCare's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: TRHC is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: TRHC's weekly volatility (6%) has been stable over the past year.


Market Performance


7 Day Return

-10.1%

TRHC

1.3%

US Healthcare Services

0.9%

US Market


1 Year Return

-26.5%

TRHC

16.5%

US Healthcare Services

37.8%

US Market

Return vs Industry: TRHC underperformed the US Healthcare Services industry which returned 16.5% over the past year.

Return vs Market: TRHC underperformed the US Market which returned 37.8% over the past year.


Shareholder returns

TRHCIndustryMarket
7 Day-10.1%1.3%0.9%
30 Day-22.5%-3.0%0.3%
90 Day-7.8%-3.0%2.1%
1 Year-26.5%-26.5%16.8%16.5%40.0%37.8%
3 Year-30.1%-30.1%130.1%128.1%63.8%53.5%
5 Yearn/a209.0%205.0%124.6%99.7%

Long-Term Price Volatility Vs. Market

How volatile is Tabula Rasa HealthCare's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Tabula Rasa HealthCare undervalued compared to its fair value and its price relative to the market?

48.0%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: TRHC ($40.73) is trading below our estimate of fair value ($78.35)

Significantly Below Fair Value: TRHC is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: TRHC is unprofitable, so we can't compare its PE Ratio to the US Healthcare Services industry average.

PE vs Market: TRHC is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate TRHC's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: TRHC is overvalued based on its PB Ratio (11.3x) compared to the US Healthcare Services industry average (6.7x).


Future Growth

How is Tabula Rasa HealthCare forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?

23.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: TRHC is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: TRHC is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: TRHC is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: TRHC's revenue (15.2% per year) is forecast to grow faster than the US market (9.2% per year).

High Growth Revenue: TRHC's revenue (15.2% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if TRHC's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Tabula Rasa HealthCare performed over the past 5 years?

-50.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: TRHC is currently unprofitable.

Growing Profit Margin: TRHC is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: TRHC is unprofitable, and losses have increased over the past 5 years at a rate of 50.5% per year.

Accelerating Growth: Unable to compare TRHC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TRHC is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (28.5%).


Return on Equity

High ROE: TRHC has a negative Return on Equity (-102.87%), as it is currently unprofitable.


Financial Health

How is Tabula Rasa HealthCare's financial position?


Financial Position Analysis

Short Term Liabilities: TRHC's short term assets ($84.9M) exceed its short term liabilities ($61.5M).

Long Term Liabilities: TRHC's short term assets ($84.9M) do not cover its long term liabilities ($357.4M).


Debt to Equity History and Analysis

Debt Level: TRHC's debt to equity ratio (412.7%) is considered high.

Reducing Debt: TRHC's debt to equity ratio has reduced from 1271.5% to 412.7% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: TRHC has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if TRHC has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is Tabula Rasa HealthCare current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate TRHC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate TRHC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if TRHC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if TRHC's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of TRHC's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.1yrs

Average management tenure


CEO

Calvin Knowlton (71 yo)

7.08yrs

Tenure

US$4,602,660

Compensation

Dr. Calvin H. Knowlton, BSc Pharm, MDiv, Ph.D., is a Co-Founder of Tabula Rasa Healthcare, Inc. and has been its Chairman and Chief Executive Officer since June 2014. Dr. Knowlton founded Tabula Rasa Healt...


CEO Compensation Analysis

Compensation vs Market: Calvin's total compensation ($USD4.60M) is above average for companies of similar size in the US market ($USD2.44M).

Compensation vs Earnings: Calvin's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: TRHC's management team is seasoned and experienced (6.1 years average tenure).


Board Members

Experienced Board: TRHC's board of directors are considered experienced (3.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: TRHC insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 14.5%.


Top Shareholders

Company Information

Tabula Rasa HealthCare, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Tabula Rasa HealthCare, Inc.
  • Ticker: TRHC
  • Exchange: NasdaqGM
  • Founded: 2009
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Market Cap: US$1.012b
  • Shares outstanding: 24.84m
  • Website: https://www.tabularasahealthcare.com

Number of Employees


Location

  • Tabula Rasa HealthCare, Inc.
  • 228 Strawbridge Drive
  • Suite 100
  • Moorestown
  • New Jersey
  • 8057
  • United States

Listings


Biography

Tabula Rasa HealthCare, Inc. operates as a healthcare technology company in the United States. The company operates through two segments, CareVention HealthCare and MedWise HealthCare. It offers EireneRx, ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/07/28 02:52
End of Day Share Price2021/07/27 00:00
Earnings2021/03/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.